肿瘤科

订阅

MedSci主页 / 所有栏目 / 肿瘤科

CLIN CANCER RES：化疗会诱导乳腺癌异常单核细胞增多相关干性

2018-06-06 MedSci MedSci原创

乳腺癌化疗单核细胞增多
关注

局部晚期或炎性乳腺癌患者接受术前或新辅助治疗正逐渐增加，以期达到更好的手术切除效果和病理学反应。但是，许多乳腺癌治疗后会耐药或复发。CLIN CANCER RES近期发表了一篇文章，研究化疗触发的促进肿瘤干细胞样亚型（CSC）发生及肿瘤复发的系统及局部变化。

局部晚期或炎性乳腺癌患者接受术前或新辅助治疗正逐渐增加，以期达到更好的手术切除效果和病理学反应。但是，许多乳腺癌治疗后会耐药或复发。CLIN CANCER RES近期发表了一篇文章，研究化疗触发的促进肿瘤干细胞样亚型（CSC）发生及肿瘤复发的系统及局部变化。

作者比较了新辅助治疗前及新辅助治疗后配对的标本中的乳腺癌CSC比例。使用细胞系，异种移植模型以及原发肿瘤研究化疗相关因素导致的CSC调节以及肿瘤进展情况。研究结果表明，在人及老鼠血清中均发现治疗诱导的CSC激活活动，其原因是治疗相关单核细胞增加导致的单核细胞趋化蛋白（MCP）增加。新辅助治疗后骨髓造血出现单核-巨噬细胞分化改变及造血干细胞相单核细胞分化异常。化疗药物还通过JNK机制诱导单核细胞MCP表达。基因或药理学方法抑制MCP-CCR2通路可以阻断化疗对CSC的不良效果。新辅助治疗后，原发乳腺癌细胞核中Notch和ALDH1水平均显着增加，而新辅助治疗前肿瘤中高水平CCR2与新辅助治疗反应不佳有关。

文章最后认为，该研究揭示了化疗诱导的肿瘤干性机制，药理学阻断CCR2可以作为常规新辅助和辅助化疗的潜在联合治疗方式。

原始出处：
Liang Liu,Lin Yang,et al.Chemotherapy Induces Breast Cancer Stemness in Association with Dysregulated Monocytosis.CLIN CANCER RES.May 2018 doi:10.1158/1078-0432.CCR-17-2545

本文系梅斯医学（MedSci）原创编译整理，转载需授权！

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=328276, encodeId=4ed83282e629, content=对研究化疗耐药的我很有用, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJE7Dkic4tYtMhNjzB43VpiaMqo01y7CBVWEg2Piby9JfvetWzibMic6IMW81lSQmGq7Hk26lDHw9WPKlg/0, createdBy=3a402138340, createdName=DDDAN, createdTime=Sat Jun 30 20:21:57 CST 2018, time=2018-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1299119, encodeId=f7541299119a5, content=<a href='/topic/show?id=2b85362063c' target=_blank style='color:#2F92EE;'>#单核细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36206, encryptionId=2b85362063c, topicName=单核细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=daa8281, createdName=雕雕, createdTime=Fri Jun 08 05:53:00 CST 2018, time=2018-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=321960, encodeId=db33321960af, content=学习了.长知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Wed Jun 06 15:44:14 CST 2018, time=2018-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=321957, encodeId=40e532195ecc, content=优质资源.共同学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K0LqDY57Aia0TOQByoJhNt3icm4sfukp500hLH6RHOpFdV01NbECtAV7s0qKpQPibyRukQAwAmqJU3X/0, createdBy=f91f1928792, createdName=九九消寒, createdTime=Wed Jun 06 15:24:35 CST 2018, time=2018-06-06, status=1, ipAttribution=)]
    2018-06-30 DDDAN

    对研究化疗耐药的我很有用

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=328276, encodeId=4ed83282e629, content=对研究化疗耐药的我很有用, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJE7Dkic4tYtMhNjzB43VpiaMqo01y7CBVWEg2Piby9JfvetWzibMic6IMW81lSQmGq7Hk26lDHw9WPKlg/0, createdBy=3a402138340, createdName=DDDAN, createdTime=Sat Jun 30 20:21:57 CST 2018, time=2018-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1299119, encodeId=f7541299119a5, content=<a href='/topic/show?id=2b85362063c' target=_blank style='color:#2F92EE;'>#单核细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36206, encryptionId=2b85362063c, topicName=单核细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=daa8281, createdName=雕雕, createdTime=Fri Jun 08 05:53:00 CST 2018, time=2018-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=321960, encodeId=db33321960af, content=学习了.长知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Wed Jun 06 15:44:14 CST 2018, time=2018-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=321957, encodeId=40e532195ecc, content=优质资源.共同学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K0LqDY57Aia0TOQByoJhNt3icm4sfukp500hLH6RHOpFdV01NbECtAV7s0qKpQPibyRukQAwAmqJU3X/0, createdBy=f91f1928792, createdName=九九消寒, createdTime=Wed Jun 06 15:24:35 CST 2018, time=2018-06-06, status=1, ipAttribution=)]
    2018-06-08 雕雕

    #单核细胞#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=328276, encodeId=4ed83282e629, content=对研究化疗耐药的我很有用, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJE7Dkic4tYtMhNjzB43VpiaMqo01y7CBVWEg2Piby9JfvetWzibMic6IMW81lSQmGq7Hk26lDHw9WPKlg/0, createdBy=3a402138340, createdName=DDDAN, createdTime=Sat Jun 30 20:21:57 CST 2018, time=2018-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1299119, encodeId=f7541299119a5, content=<a href='/topic/show?id=2b85362063c' target=_blank style='color:#2F92EE;'>#单核细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36206, encryptionId=2b85362063c, topicName=单核细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=daa8281, createdName=雕雕, createdTime=Fri Jun 08 05:53:00 CST 2018, time=2018-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=321960, encodeId=db33321960af, content=学习了.长知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Wed Jun 06 15:44:14 CST 2018, time=2018-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=321957, encodeId=40e532195ecc, content=优质资源.共同学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K0LqDY57Aia0TOQByoJhNt3icm4sfukp500hLH6RHOpFdV01NbECtAV7s0qKpQPibyRukQAwAmqJU3X/0, createdBy=f91f1928792, createdName=九九消寒, createdTime=Wed Jun 06 15:24:35 CST 2018, time=2018-06-06, status=1, ipAttribution=)]
    2018-06-06 1ddf0692m34(暂无匿称)

    学习了.长知识

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=328276, encodeId=4ed83282e629, content=对研究化疗耐药的我很有用, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJE7Dkic4tYtMhNjzB43VpiaMqo01y7CBVWEg2Piby9JfvetWzibMic6IMW81lSQmGq7Hk26lDHw9WPKlg/0, createdBy=3a402138340, createdName=DDDAN, createdTime=Sat Jun 30 20:21:57 CST 2018, time=2018-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1299119, encodeId=f7541299119a5, content=<a href='/topic/show?id=2b85362063c' target=_blank style='color:#2F92EE;'>#单核细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36206, encryptionId=2b85362063c, topicName=单核细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=daa8281, createdName=雕雕, createdTime=Fri Jun 08 05:53:00 CST 2018, time=2018-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=321960, encodeId=db33321960af, content=学习了.长知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Wed Jun 06 15:44:14 CST 2018, time=2018-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=321957, encodeId=40e532195ecc, content=优质资源.共同学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K0LqDY57Aia0TOQByoJhNt3icm4sfukp500hLH6RHOpFdV01NbECtAV7s0qKpQPibyRukQAwAmqJU3X/0, createdBy=f91f1928792, createdName=九九消寒, createdTime=Wed Jun 06 15:24:35 CST 2018, time=2018-06-06, status=1, ipAttribution=)]
    2018-06-06 九九消寒

    优质资源.共同学习

    0

相关资讯

ASCO 2018：乳腺癌抗HER2辅助治疗，6个月就足够了？

摘要编号：506时间：6月4日8:00 AM~11:00 AM专场：局部乳腺癌/区域乳腺癌/新辅助治疗形式：口头报告  对于HER2阳性乳腺癌而言，曲妥珠单抗1年辅助治疗是目前各大指南推荐的标准方案。曾有多项研究试图在不影响疗效的前提下缩短抗HER2治疗时间，但均未能取得成功。 PERSEPHONE研究是一项由英国研究者开展的大型多中心、非劣效、随机对照Ⅲ期临床试验，

NEJM：绝经期前乳腺癌患者辅助内分泌治疗效果研究

研究认为，对于绝经期前乳腺癌患者，依西美坦联合卵巢抑制可获得最佳的长期疾病缓解效果

CLIN CANCER RES：乳腺癌雄激素受体阳性程度对预测疾病预后至关重要

目前，雄激素受体（AR）作为乳腺癌预后因素尚缺乏共识。CLIN CANCER RES近期发表了一篇文章，对雄激素受体预后有关的研究进行综述，确定雄激素受体作为乳腺癌预后独立预测因素的关键标准。

Lancet oncol：ABP980，曲妥珠单抗的生物类似物，用于HER2阳性的乳腺癌患者的效果和安全性，与曲妥珠单抗的不相上下

ABP980是曲妥珠单抗的生物类似物，与曲妥珠单抗具有相似的分析、功能和药代动力学。现研究人员在多个国家的97个研究中心开展一随机的、多中心、双盲、活性对照的等效试验，对比ABP980与曲妥珠单抗用于HER2阳性的早期乳腺癌的效果和安全性。招募年满18岁的组织学确诊的HER2阳性的侵袭性早期乳腺癌患者，ECOG表现评分0-1分、计划进行采样手术切除肿瘤以及前哨或腋窝淋巴结清扫和新辅助化疗。经过4个

JCO：Ribociclib联合Fulvestrant治疗激素受体阳性，HER2阴性晚期乳腺癌

JCO近期发表了一篇文章，研究Ribociclib联合Fulvestrant治疗激素受体阳性/HER2阴性，未接受过治疗或接受过内分泌治疗的晚期乳腺癌患者的效果。

NEJM：21基因乳腺癌复发风险评分与化疗

对于21基因乳腺癌复发风险评分11-25分的患者，仅接受内分泌治疗即可实现对疾病的有效控制